Short courses of chemotherapy followed by 90Y-Ibritumomab tiuxetan for relapsed low grade B cell lymphoma

Short courses of chemotherapy followed by 90Y-Ibritumomab tiuxetan for relapsed low grade B cell lymphoma - CLOBRZ study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012957

Enrollment

Registered

2014-01-25

Start date

2014-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed low grade B cell lymphoma

Interventions

2~3 courses of chemotherapy followed by Y90-Ibritumomab tiuxetan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Relapsed low grade lymphoma patients who require treatment Measurable lymphoma lesion that is more than 2cm PS 0~2

Exclusion criteria

Exclusion criteria: Uncontrollable severe complications Neutrophils <1200/ul, Platelets <100000/ul

Design outcomes

Primary

Measure	Time frame
CR rate	—

Secondary

Measure	Time frame
Completion rate, PFS, TTNT(Time to next treatment)	—

Countries

Japan

Contacts

Public ContactTetsuya Fukuda

Tokyo Medical and Dental University Department of Hematology

fuku.hema@tmd.ac.jp81-3-5803-5211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026